Paris, France
Paris, France

Time filter

Source Type

News Article | October 28, 2016
Site: www.prweb.com

The LASIK Vision Institute (LVI) announced today that it is opening a new laser eye surgery center in Lubbock, Texas. LVI has more than 70 LASIK centers in the United States, and the company has performed more than 1.1 million laser vision correction procedures. The new LASIK center in Lubbock is equipped with state-of-the-art technology to ensure the best possible care for each patient. LVI’s highly trained and experienced independent surgeons will help eligible patients improve their vision and enjoy more of their lives with less dependency on glasses or contacts. “Safe, affordable and high-quality vision correction is an incredible service that we offer,” said CEO Ben Cook. “Enjoying more activities with less reliance on contacts of glasses has made life easier for me and for many of the patients we have helped at LVI locations nationwide.” The Lubbock LASIK center will also service the neighboring towns of Guthrie, Plainview, Midland, Sweetwater, Abilene and many others. The center, the eighth LVI facility in Texas, will be located at 5307 West Loop 289 Suite 105, Lubbock, TX 79414. Patients interested in learning more about LVI’s services are encouraged to schedule a free LASIK evaluation. The top national provider of laser vision correction, The LASIK Vision Institute (LVI) operates a growing nationwide network. The company utilizes safe, FDA approved, advanced LASIK technology. LVI’s highly skilled LASIK surgeons have performed more than one million procedures. For more information, visit The LASIK Vision Institute.


News Article | November 30, 2016
Site: www.prweb.com

The Lubbock Chamber of Commerce today hosted a ribbon cutting at The LASIK Vision Institute’s (LVI) new laser vision correction center. The center is LVI’s first in Lubbock and eighth location in Texas. The event took place on November 30 at 9:30 a.m. After a brief introduction about the center, attendees observed a ceremonial ribbon cutting. Those in attendance included The LASIK Vision Institute staff and Chamber Ambassadors from the Lubbock Chamber of Commerce. Following the ceremony, guests were invited to treat themselves to complimentary light refreshments. “We are thrilled to be opening this facility, which will provide safe and affordable vision correction to the people of Lubbock and its surrounding areas,” said LVI CEO Ben Cook. “It’s simple: when you see better, you live better.” The LASIK Vision Institute is an industry leader, having successfully completed more than 1.1 million laser vision correction procedures. With more than 80 centers across the United States and payment options for nearly every budget, LVI is committed to convenience and affordability. Like all LVI facilities, the new center in Lubbock is equipped with state-of-the-art technology and staffed by highly trained, experienced independent surgeons and medical staff. The new Lubbock center is located at 5307 West Loop 289 Suite 105, Lubbock, TX 79414. To learn more about LVI’s vision correction options, schedule a free evaluation today. The top national provider of laser eye surgery, The LASIK Vision Institute (LVI) operates a growing nationwide network. The company utilizes safe, FDA-approved, advanced LASIK technology. LVI’s highly skilled independent LASIK surgeons have performed more than 1.1 million procedures. For more information, visit The LASIK Vision Institute.


News Article | October 29, 2016
Site: www.prweb.com

The LASIK Vision Institute (LVI) announced today that it will expand into a new location in Columbia, South Carolina. The third location in South Carolina, this brand new facility will offer top-quality laser eye surgery at affordable prices. LVI is the nation’s leader in LASIK, and the new facility will be equipped with state-of-the-art laser vision correction equipment. The expert, independent LASIK surgeons at the new Columbia laser eye surgery center are dedicated to performing safe procedures that offer patients the opportunity to see more clearly with less reliance on contacts or glasses. LVI’s FDA-approved laser technology and highly- qualified staff are prepared to treat patients who are nearsighted, farsighted or have astigmatism. Residents of South Carolina can make an appointment for a free evaluation with no obligation to see if they are a candidate for laser eye surgery. “Being able to see more clearly with less dependency on glasses or contacts changes people’s lives,” said LVI CEO Ben Cook. “With LVI’s new center in Columbia, we’ll be able to help more people get more out of life, and I’m so proud of that.” LVI’s new Columbia LASIK Vision Center is located at 1021 Pinnacle Point Columbia, SC 29223, conveniently located off Interstate 77. This location will also serve residents of Aiken, Florence, Elgin, Irmo, Sumter, Swansea and Camden. To schedule your free consultation at LVI in Columbia, please visit http://www.lasikvisioninstitute.com/lasik-eye-surgery/columbia-sc-surgeon-center/. The top national provider of laser eye surgery, The LASIK Vision Institute (LVI) operates a growing nationwide network. The company utilizes safe, FDA approved, advanced LASIK technology. LVI’s highly skilled LASIK surgeons have performed more than one million procedures. For more information, visit The LASIK Vision Institute.


Pflugfelder S.C.,Baylor College of Medicine | Baudouin C.,Quinze Vingts Hospital | Baudouin C.,Vision Institute
Clinical Ophthalmology | Year: 2011

Ocular surface disease (OSD) is common among glaucoma patients. Clinical assessment of OSD can be challenging. This review focuses on some of the limitations relating to both subjective and objective measures of OSD, including dry eye. A survey of the literature was conducted to identify the caveats associated with different methods of assessing OSD. The effect of preservatives on the ocular surface, with respect to glaucoma patients in particular, was also reviewed. Objective methods for assessing ocular surface health and disease include the Schirmer test, tear break-up time, fluorescein turnover, corneal and conjunctival staining, tear osmolarity, and vital dyes. These measures all have limitations in terms of their ability to grade the severity of OSD. Previous studies using the OSD Index showed a mild-to-moderate correlation to dry eye disease severity. Other scoring systems for dry eye have shown a relationship to patient symptom scores or quality of life. Due to the challenges clinicians face concerning both subjective and objective ocular surface health assessments, discerning clinical improvement in ocular surface disease can be a challenge. Further research is needed in order to optimize existing clinical methods and/or identify alternative techniques for assessing OSD in the glaucoma population. © 2011 Pflugfelder and Baudouin.


ROMAINVILLE, France, Nov. 30, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat aging diseases, announces the successful completion of its SARA-PK clinical study for Sarconeos, lead drug candidate for the treatment of sarcopenia. The results of the study, conducted in young and elderly healthy volunteers, confirmed Sarconeos’ appropriate safety profile, with no serious adverse events associated with the administration of Sarconeos. Stanislas Veillet, Chief Executive Officer of BIOPHYTIS, said: “The successful outcome of the SARA-PK study is an important milestone for BIOPHYTIS and our Sarconeos development program. We have strong confidence in Sarconeos’ safety profile and will move forward with our Phase 2b SARA-INT study in 2017, as planned.  We believe Sarconeos is well differentiated and has significant potential to treat sarcopenia, a debilitating muscle wasting disease that is largely untreatable today.” The objective of the SARA-PK study was to assess the safety, tolerability and pharmacokinetic profile of Sarconeos in elderly healthy volunteers (> 65 years old).  The study was conducted in two phases: single ascending dose (SAD) administration, and multiple ascending dose (MAD) administration.  The MAD portion of the study was aimed at evaluating the safety and pharmacokinetics of Sarconeos in 30 older subjects, following three ascending oral administrations daily for 14 days (350mg/day, 700 mg/day then 900 mg/day).  Both phases of the SARA-PK study have now been successfully completed. The results of the SARA-PK study will be used to select the two doses of Sarconeos for further evaluation in the Phase 2b SARA-INT trial, which BIOPHYTIS intends to initiate in the first half of 2017. The complete results of the SARA-PK study, in particular the pharmacokinetic profile of Sarconeos, will be available in the first quarter of 2017. Initial study results will be presented at the 9th International Conference on Sarcopenia, Cachexia, and muscle Wasting Diseases (SCWD), being held December 10-11, 2016, in Berlin, Germany. About SARCONEOS: Sarconeos is the first representative of a new class of drug candidates, based on the activation of the MAS receptor (major player of the renin-angiotensin system) stimulating anabolism in the muscle, inhibitor of myostatin and favoring muscle mass development in animal models of muscular dystrophies. Sarconeos is developed in the treatment of sarcopenia, an age-related degeneration of skeletal muscle and strength, leading to a loss of mobility in elderly people. This new pathology, for which no medical treatment currently exists, was first described in 1993 and just entered the WHO International Classification of Diseases (M62.84), affects more than 50 million people worldwide. About BIOPHYTIS: BIOPHYTIS SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre et Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute. BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN: FR0012816825). For more information: http://www.biophytis.com BIOPHYTIS is eligible for the Equity Saving Plans PEA-PME. Disclaimer This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf- france.org) or on BIOPHYTIS’ website (www.biophytis.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.


ROMAINVILLE, France, Nov. 15, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of aging, announced today that four posters on Sarconeos (BIO101), the Company’s lead drug candidate for the treatment of sarcopenia, have been accepted for presentation at the 9th International Conference on Cachexia, Sarcopenia and Muscle Wasting, being held December 10-11, 2016 in Berlin, Germany. Stanislas Veillet CEO BIOPHYTIS, said: "Sarcopenia, or muscle wasting, is a growing problem as the world population continues to age and live longer. Having four poster presentations focusing on Sarconeos at a conference specifically tailored to and attended by key opinion leaders in muscular dystrophies is the perfect opportunity to showcase to key opinion leaders its method of action, clinical development, and patient outcomes observed to date.” About The Society on Sarcopenia, Cachexia, and Wasting Disorders (SCWD) The Society on Sarcopenia, Cachexia, and Wasting Disorders was founded in 2008 on the initiative of Dr. Stefan D. Anker and Dr. John E. Morley, whose leadership and vision guided the expansion of clinical expertise and research in this field. The Society on Sarcopenia, Cachexia and Wasting Disorders is a non-profit scientific organization comprised of an international and multidisciplinary group of health-care professionals primarily active in these fields. The SCWD seeks to further research on cachexia and sarcopenia and wasting disorders and bring practical solutions to health-care teams worldwide grappling with treatment. The spectrum of clinical disorders represented by the SCWD Society includes, but is not limited to cachexia, sarcopenia, the syndrome of muscle wasting associated to cancer, COPD, diabetes, heart failure, aging and other chronic conditions.  In recent years, there has been tremendous growth in new diagnostic information, pharmacological and nutritional treatments for wasting disorders, as well as a greater number of associated clinical trials. About SARCONEOS (BIO101) Sarconeos is a first in class drug candidate based on the activation of the Mas receptor (major player of the renin-angiotensin system) restoring muscular anabolism, inhibiting myostatin, that has demonstrated meaningful activity in animal models of muscular dystrophies. Sarconeos is developed in the treatment of sarcopenia, an age-related degeneration of skeletal muscle, leading to loss of mobility in elderly people. This condition, for which no medical treatment currently exists, was first described in 1993 and has entered the International Classification of Diseases (M62.84) in 2016. It affects more than 50 million people worldwide. About BIOPHYTIS: BIOPHYTIS SA (www.BIOPHYTIS.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute. BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN:FR0012816825). Disclaimer This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS’ website (www.BIOPHYTIS.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.


PARIS, March 02, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of ageing, announces today the complete results of the SARA-PK study, in particular the favorable pharmacokinetics and pharmacodynamics of Sarconeos. The analyses confirm the good pharmacokinetic profile in healthy elderly volunteers, the therapeutic window of Sarconeos, and confirms the dosages that will be tested in the Phase 2b trial SARA-INT. The study’s complete results will be presented at the International ICFSR on April 28th in Barcelona. Stanislas Veillet, CEO of BIOPHYTIS, declares: “The analysis of the complete results of the SARA-PK trial confirms Sarconeos’ good pharmacokinetic profile and allows us to determine the doses that will be tested in the Phase 2b study, SARA-INT, which we hope to start in mid-2017. These data will be used now to complete the regulatory filings required for the authorizations to start in U.S. and Europe SARA-INT, the interventional Phase 2b trial in sarcopenia patients." Safety data collected at the end of SARA-PK had already confirmed the good tolerability profile and the absence of any serious adverse event associated with the administration of Sarconeos. These safety results had already been presented at the 9th international conference on Cachexia, Sarcopenia and muscle Wasting Disease (SCWD) held in Berlin last December. The complete results of the SARA-PK study, in particular the pharmacokinetic profile of the Sarconeos product, have now been analyzed and top-line data are being communicated today for the first time. The main parameters of the pharmacokinetics (half-life, area under curve, maximum plasma concentration of the product, etc.) have been estimated, allowing the confirmation of Sarconeos’ good pharmacokinetic profile in healthy elderly volunteers, which is not significantly different from the profile observed in adult volunteers. The qualitative study of biomarkers of muscular metabolism (creatine kinase, myoglobin, etc.) and of the renin-angiotensin system (renin, adolsterone, etc.) gathered at the end of the trial, allows for the description of Sarconeos’ pharmacodynamic profile. The study of Sarconeos’ effects on these biomarkers in SARA-INT should allow the confirmation of these patterns. The complete analysis of the safety, pharmacokinetic and pharmacodynamic data allows the confirmation of Saconeos’ favorable therapeutic window and the selection of the two doses which will be tested in the placebo-controlled Phase 2b SARA-INT trial, provided it is authorized by the relevant regulatory agencies. The selected oral doses are: 175 mg twice-daily and 350mg twice-daily. The complete results of the SARA-PK study will be presented in an oral presentation at the ICFSR (International Conference on Frailty & Sarcopenia Research), which will take place in Barcelona from April 27th to 29th of. The title of the presentation will be: “SARA-PK: A single and multiple ascending oral doses study to assess the safety and evaluate the pharmacokinetics of BIO101 in healthy young and older volunteers”. An abstract of the presentation also will be published in a special edition of the scientific review The Journal of Frailty & Aging. About SARA-PK: The objective of the SARA-PK study was to evaluate safety, tolerance and the pharmacokinetic profile of Sarconeos in healthy elderly volunteers (>65 years). The study was carried out in two phases: the administration of a single ascending dose (SAD), and multiple ascending doses (MAD). The second stage of the study – MAD (multiple ascending doses) – which has just been reached, had as its objective the evaluation of the safety, tolerance and pharmacokinetics of Sarconeos in subjects aged 30, after the oral administration of 3 multiple ascending doses (350mg/day, 700 mg/day then 900 mg/day) every day over 14 days. Both phases of the SARA-PK study were carried out successfully. About BIOPHYTIS: BIOPHYTIS SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). Located on the Pierre et Marie Curie University (UPMC) campus in Paris, BIOPHYTIS also collaborates with scientists at the Institute of Myology, and the Vision Institute. BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN: FR0012816825). For more information: http://www.biophytis.com BIOPHYTIS is eligible for the SMEs scheme. Disclaimer This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS’ website (www.biophytis.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.


The International Association of HealthCare Professionals is pleased to welcome Kinga Michelle Huzella, MD, Ophthalmologist, to their prestigious organization with her upcoming publication in The Leading Physicians of the World. She is a highly-trained and qualified ophthalmologist with an extensive expertise in all facets of her work, especially glaucoma and cornea treatments. Dr. Kinga Michelle Huzella has been in practice for more than 25 years and is currently serving patients at Maryland Vision Institute in Hagerstown, Maryland. Dr. Kinga Michelle Huzella’s career in medicine began in 1991 when she graduated with her Medical Degree from the Jacobs School of Medicine at the State University of New York at Buffalo. Following her graduation, Dr. Huzella went on to complete her internship at the University of Virginia Health Sciences Center, followed by her residency at New York’s Brookdale University Hospital and Medical Center, where she served as Chief Resident. Furthermore, Dr. Huzella is board certified by the American Board of Ophthalmology. To keep up to date with the latest advances and developments in her field, Dr. Huzella maintains a professional membership with the American Academy of Ophthalmology, the Maryland Society of Eye Physicians and Surgeons, the Hungarian Medical Association of America, and Women in Ophthalmology. Dr. Huzella attributes her success to the love and encouragement of her parents, her great work ethic, her passion and compassion for her patients, and the support from her husband. When she is not assisting her patients, Dr. Huzella enjoys playing the piano, animals, traveling, aerobics, jogging, tennis, and spending time with her family. Learn more about Dr. Huzella by reading her upcoming publication in The Leading Physicians of the World. FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics.  Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review.  FindaTopDoc.com features each doctor’s full professional biography highlighting their achievements, experience, patient reviews and areas of expertise.  A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life.  For more information about FindaTopDoc, visit http://www.findatopdoc.com


Rogister P.,ETH Zurich | Benosman R.,Vision Institute | Ieng S.-H.,Vision Institute | Lichtsteiner P.,ETH Zurich | Delbruck T.,ETH Zurich
IEEE Transactions on Neural Networks and Learning Systems | Year: 2012

We present a novel event-based stereo matching algorithm that exploits the asynchronous visual events from a pair of silicon retinas. Unlike conventional frame-based cameras, recent artificial retinas transmit their outputs as a continuous stream of asynchronous temporal events, in a manner similar to the output cells of the biological retina. Our algorithm uses the timing information carried by this representation in addressing the stereo-matching problem on moving objects. Using the high temporal resolution of the acquired data stream for the dynamic vision sensor, we show that matching on the timing of the visual events provides a new solution to the real-time computation of 3-D objects when combined with geometric constraints using the distance to the epipolar lines. The proposed algorithm is able to filter out incorrect matches and to accurately reconstruct the depth of moving objects despite the low spatial resolution of the sensor. This brief sets up the principles for further event-based vision processing and demonstrates the importance of dynamic information and spike timing in processing asynchronous streams of visual events. © 2012 IEEE.


News Article | October 28, 2016
Site: www.prweb.com

Industry leader Vision Group Holdings (VGH) announced today that it has acquired Fisher Eye & Laser Center in Naples, Florida. The company, headquartered in West Palm Beach, operates numerous laser eye surgery centers in the state of Florida, but this will be the first LASIK center in Naples. VGH operates the well-known brands The LASIK Vision Institute and TLC Laser Eye Centers, as well as many others. Between all its brands, VGH has successfully completed more than 3.3 million laser eye procedures, making it by far the largest provider of LASIK in North America. A full-service facility with state-of-the-art technology, Fisher Eye & Laser Center has already established itself as an outstanding center for vision correction. Its attentive staff will continue to provide high-quality service to all of the center’s patients. Dr. G. Brit Fisher III, the facility’s independent surgeon, will remain at the center as well. As founder of Fisher Eye & Laser Center, Dr. Fisher has been performing vision correction procedures in Naples since 1999, and he will continue to treat each of his patients with the care and respect they have come to expect. “By partnering with Vision Group Holdings, I will be able to focus even more of my attention on the most important aspect of my job – my patients,” said Dr. Fisher. “This will allow us to help more Floridians see more clearly while ensuring that each of them gets the personalized care they expect from Fisher Eye & Laser Center.” Vision Group Holdings CEO Ben Cook added: “Dr. Fisher is an extremely skilled and experienced surgeon. He and his associates provide superior service, and we could not be more pleased to welcome them to our growing network of LASIK providers.” Fisher Eye & Laser Center will continue to operate from its current location at 875 105th Avenue North, Naples, FL 34108. To learn more or to schedule an appointment, visit http://www.fishereyecenter.com. Vision Group Holdings, based in West Palm Beach, Florida, oversees and manages two of the leading LASIK surgery providers in the world: The LASIK Vision Institute and TLC Laser Eye Centers. Between the two brands, the company has performed over 3.3 million LASIK eye procedures. Vision Group Holdings, the largest LASIK provider in North America, serves multiple markets in the United States and Canada, making it extremely convenient for patients to find a location that is both nearby and well suited to their specific needs.

Loading Vision Institute collaborators
Loading Vision Institute collaborators